EGFR Chimeric Antigen Receptor (CAR): A Comprehensive Guide and Our Service & Product Introduction

EGFR (Epidermal Growth Factor Receptor) is a crucial target in tumor immunotherapy, and EGFR Chimeric Antigen Receptors (CARs) have become a research hotspot in the field of targeted cancer treatment. RGBiotech is committed to providing high-quality EGFR CAR expression plasmid vectors and professional custom vector construction services, supporting global researchers and biopharmaceutical enterprises in advancing EGFR-targeted immunotherapy research and clinical transformation.

Our EGFR CAR Expression Plasmid Vector Products and Custom Services

RGBiotech has long been engaged in the research and development, production and customization of gene engineering vectors, and has rich experience in the field of EGFR CAR. We provide a full range of EGFR CAR expression plasmid vector products and professional custom vector construction services to meet the diverse research needs of researchers and enterprises. If you need more information about our EGFR CAR products and custom services, please contact us at admin@rgbiotech.com. We will wholeheartedly provide you with professional services and support.

Our EGFR CAR expression plasmid vectors cover different generations of CAR designs, with diverse vector backbones, which can effectively support the research and application of EGFR CAR.

1) Covers Multiple Generations of EGFR CAR: Including first-generation, second-generation, third-generation and fourth-generation EGFR CAR vectors. First-generation CAR only contains CD3ζ intracellular signaling domain, which can activate T cell cytotoxicity but has weak persistence; second-generation CAR adds one co-stimulatory domain (CD28 or 4-1BB), which can enhance T cell proliferation and anti-apoptosis ability; third-generation CAR contains two co-stimulatory domains (such as CD28+4-1BB), which further improves the activation and persistence of T cells; fourth-generation CAR (also known as armored CAR) adds cytokine (IL-12, IL-15, etc.) or immune checkpoint inhibitor (PD-1 scFv) coding sequences, which can resist the immunosuppressive tumor microenvironment and enhance the anti-tumor effect. We also provide Binder-based EGFR CAR vectors, which have higher stability and tumor-killing ability than traditional scFv-based CAR vectors.

2) Diverse Vector Backbones: We provide a variety of vector backbones to meet different delivery needs, including non-viral vectors (plasmid vectors, transposon vectors) and viral vectors (lentiviral vectors, retroviral vectors, AAV vectors). Lentiviral vectors have high transduction efficiency and can transduce both dividing and non-dividing cells, which is suitable for T cell modification; retroviral vectors are suitable for stable transduction of dividing cells; AAV vectors have low immunogenicity and high safety, which is suitable for in vivo delivery; non-viral vectors have the advantages of low cost, easy large-scale production.

3) Optimized Promoters: The vectors are equipped with high-efficiency promoters to ensure high-level expression of EGFR CAR in target cells. Common promoters include CMV promoter (strong constitutive expression), EF1α promoter (stable expression in mammalian cells, low silencing rate), and tissue-specific promoters (optional according to research needs), which can meet different expression requirements.

3) Fluorescent Labeling Options: To facilitate the detection and sorting of CAR-positive cells, our vectors are equipped with fluorescent reporter genes, including GFP (green fluorescent protein), mCherry (red fluorescent protein), CFP (cyan fluorescent protein), etc. The fluorescent label is linked to the CAR or the antibiotic selection marker gene through a 2A peptide (T2A, P2A, etc.), which ensures the co-expression of CAR and fluorescent protein, and does not affect the structure and function of CAR.

4) Antibiotic Selection Markers: The vectors contain antibiotic selection markers to facilitate the screening of positive clones during vector construction and cell transduction. Common selection markers include ampicillin (for prokaryotic cells), kanamycin (for prokaryotic cells), neomycin (G418, for eukaryotic cells), puromycin (for eukaryotic cells), blasticidin, etc. Customers can choose the appropriate selection marker according to their experimental needs.

Product Advantages

1) High Quality and Stability: Our vectors are constructed by professional technicians, and undergo strict quality control and verification to ensure the correctness of the sequence.

2) High Compatibility: The vectors are compatible with a variety of host cells, including human T cells, mouse T cells, NK cells, and various tumor cell lines, which can meet the needs of different experimental models.

3) Customizable Flexibility: On the basis of standard products, we can provide personalized modification according to customers' research needs, such as replacing promoters, fluorescent labels, selection markers, modifying CAR structure (such as adding masked linkers), and adjusting vector backbones.

4) Cost-Effective: We provide high-quality products at competitive prices, and support large-scale purchase with preferential policies, which can reduce the research cost of customers. At the same time, the vectors are easy to use, which can save experimental time and improve experimental efficiency.

5) Comprehensive Technical Support: We have a professional technical team to provide comprehensive technical support for customers, to help customers smoothly carry out research work.

Product Applications

1) Basic Research: Used for the research on the mechanism of EGFR CAR, such as the activation mechanism of CAR-T cells, the interaction between CAR and EGFR, the influence of CAR structure on T cell function, etc.

2) Preclinical Research: Used for the preparation of EGFR CAR-T/NK cells, in vitro tumor killing experiments, animal model experiments (such as xenograft mouse models), evaluation of the therapeutic effect and safety of EGFR CAR, and optimization of CAR structure and treatment strategy.

3) Drug Screening: Used for the screening of EGFR CAR synergistic drugs, such as immune checkpoint inhibitors, cytokines, etc., to explore the optimal combination therapy strategy.

EGFR CAR Plasmid Vector Custom Construction Services

In addition to standard products, we also provide professional EGFR CAR plasmid vector custom construction services to meet the personalized needs of customers. Whether you need to design a new EGFR CAR structure, modify the existing vector, or construct a vector with special functions, our professional team can provide you with one-stop custom services.

1) Custom Design of EGFR CAR Structure: According to customers' research needs, design first-generation to fourth-generation EGFR CAR structures.

2) Vector Backbone Customization: Select appropriate vector backbones (non-viral, lentiviral, retroviral, AAV, etc.) according to customers' delivery methods and experimental models.

3) Modification of Functional Elements: Customize promoters, fluorescent labels, antibiotic selection markers etc., such as replacing with tissue-specific promoters, adding dual fluorescent labels, or designing marker-free vectors.

4) Construction of Special Vectors: Construct masked EGFR CAR vectors, conditional activation CAR vectors, cytokine-secreting CAR vectors, or EGFR bispecific CAR vectors (such as EGFR/CD276 bispecific CAR) according to customers' needs.

5) Vector Optimization: Optimize the vector sequence (such as codon optimization of EGFR CAR gene) to improve the expression level of CAR in target cells, enhance the stability of the vector, and reduce the immunogenicity of the vector.

Custom Service Advantages

1) Professional Team: Our team is composed of experienced molecular biologists and genetic engineers, who are familiar with the design and construction of EGFR CAR vectors and have rich experience in solving various technical problems in vector construction.

2) Efficient Service: We have a mature vector construction process, which can complete the custom construction of vectors in the shortest time while ensuring quality.

3) Personalized Solution: We fully communicate with customers to understand their research needs and provide personalized vector design and construction solutions to ensure that the custom vector meets the specific requirements of the experiment.

4) Strict Quality Control: All custom vectors undergo the same strict quality control as standard products to ensure product quality and reliability.

5) One-Stop Service: We provide one-stop services from vector design, construction, quality control to delivery, and provide follow-up technical support to help customers solve problems encountered in the use of vectors.

Introduction of EGFR

EGFR, also known as HER1 (Human Epidermal Growth Factor Receptor 1), is encoded by the EGFR gene located on human chromosome 7p12. The EGFR gene spans approximately 118 kb, contains 28 exons, and encodes a transmembrane glycoprotein with a molecular weight of about 170 kDa. The gene sequence is highly conserved among species, and its mutations or amplification are closely related to the occurrence and development of various tumors. Common EGFR gene mutations include exon 19 deletion, exon 21 L858R point mutation, and exon 20 insertion mutation (Ex 20 ins), among which exon 19 deletion and L858R mutation are classified as sensitive mutations, accounting for 70%-80% of all EGFR mutations in lung cancer. The EGFR gene ID in NCBI GenBank is NM_005228.5 (human) and NM_010110.4 (mouse), which provides a clear genetic basis for the design and development of EGFR-targeted drugs and CAR vectors.

The EGFR protein is a member of the ErbB family of transmembrane tyrosine kinase receptors, consisting of three main structural domains: an extracellular ligand-binding domain (ECD), a transmembrane domain (TMD), and an intracellular tyrosine kinase domain (TKD). The extracellular domain is composed of 621 amino acids, including four subdomains (I-IV), among which subdomains II and IV are responsible for ligand binding, and subdomain III is involved in receptor dimerization. The transmembrane domain is a single α-helix structure composed of 23 hydrophobic amino acids, which anchors the protein to the cell membrane. The intracellular domain includes a tyrosine kinase region and a C-terminal regulatory region; the tyrosine kinase region can catalyze the phosphorylation of its own tyrosine residues and downstream substrate proteins after activation, while the C-terminal region contains multiple tyrosine phosphorylation sites that mediate the recruitment of downstream signaling molecules. The cryo-EM structure of the extracellular module of the full-length EGFR bound to TGF-alpha (PDB: 7sz5) has been resolved, providing a detailed structural basis for understanding EGFR activation and targeted drug design.

EGFR plays a key role in regulating normal cell growth, proliferation, differentiation, migration, apoptosis and angiogenesis under physiological conditions. When EGFR binds to its ligands (such as EGF, TGF-α, etc.), it undergoes homodimerization or heterodimerization with other ErbB family members (such as HER2, HER3), which activates the intracellular tyrosine kinase activity, triggers the phosphorylation of tyrosine residues in the C-terminal region, and further activates downstream signaling pathways, including MAPK/ERK, PI3K/AKT, and JAK/STAT pathways. These signaling pathways synergistically regulate cell cycle progression, promote cell proliferation, inhibit apoptosis, and enhance cell migration and invasion ability. Recent studies have found that activated EGFR can be localized on the lysosomal membrane and act as a Rheb-GEF independent of its kinase activity to activate mTORC1, thereby promoting tumor cell proliferation, which enriches the understanding of EGFR's non-classical functional mechanisms.

EGFR is widely expressed in various normal tissues and organs, especially in epithelial tissues with high proliferation activity, such as the skin, gastrointestinal tract, respiratory tract, and urinary tract epithelium. In normal tissues, EGFR is moderately expressed and tightly regulated to maintain the normal physiological functions of cells. However, in many tumor tissues, EGFR is abnormally overexpressed or mutated, leading to the continuous activation of downstream signaling pathways, which drives the malignant proliferation and metastasis of tumor cells. For example, EGFR is overexpressed in more than 80% of glioblastoma (GBM) patients, and the EGFRvⅢ mutation (a common mutant form of EGFR) has a coding mutation rate of about 50% in GBM, and specifically exists in 28%-30% of GBM cells. In non-small cell lung cancer (NSCLC), the EGFR mutation rate is as high as 49% in some Asian populations, which is significantly higher than that in European and American populations (12%-15%).

Abnormal expression or mutation of EGFR is closely related to the occurrence and development of various malignant tumors, making it an important target for tumor targeted therapy. The main EGFR-related tumors include: Non-Small Cell Lung Cancer (NSCLC), which is the most common tumor related to EGFR mutations, especially in non-smokers, women and younger patients; Glioblastoma (GBM), the most common primary malignant tumor of the central nervous system in adults, with poor prognosis, and EGFR abnormal expression is one of its key molecular characteristics; Colorectal Cancer (CRC), about 70% of colorectal cancer patients have EGFR overexpression, which is related to tumor invasion and metastasis; Head and Neck Squamous Cell Carcinoma (HNSCC), EGFR overexpression is found in more than 90% of patients, which is associated with poor prognosis; In addition, EGFR is also abnormally expressed in pancreatic cancer, breast cancer, ovarian cancer and other tumors. In addition to tumors, EGFR abnormalities are also related to some non-tumor diseases, such as psoriasis, chronic obstructive pulmonary disease (COPD), and diabetic retinopathy.

Introduction of EGFR CAR

Chimeric Antigen Receptor (CAR) is a genetically engineered receptor that can specifically recognize tumor-associated antigens (TAAs) and activate T cells to kill tumor cells. EGFR CAR is a CAR molecule designed with EGFR as the target antigen, which is composed of three core components: an extracellular antigen-binding domain (usually a single-chain variable fragment, scFv, that specifically binds to EGFR), a transmembrane domain (responsible for anchoring the CAR molecule to the T cell membrane), and an intracellular signaling domain (responsible for activating T cell proliferation, differentiation and cytotoxicity after recognizing EGFR-positive tumor cells). In recent years, researchers have also developed a new type of EGFR CAR using a mini binding protein (Binder) instead of the traditional scFv as the antigen-binding domain, which has higher stability and tumor-killing ability.

Current Research Achievements of EGFR CAR

In recent years, EGFR CAR research has made remarkable progress, especially in the treatment of solid tumors such as GBM and NSCLC, showing good therapeutic potential.

1)Treatment of Glioblastoma: Researchers from Massachusetts General Hospital in the United States designed a CAR-T therapy (CARv3-TEAM-E T) that can simultaneously target EGFRvⅢ mutation and wild-type EGFR through T cell-binding antibody molecules. In a clinical study of 3 patients with recurrent GBM, the therapy significantly reduced tumors, and 1 patient achieved complete tumor disappearance. All patients had good tolerance to the infusion, and only mild adverse reactions such as fever occurred within the expected range. Researchers from West Lake University in China designed a new type of EGFR Binder CAR using computational protein design methods. Compared with the traditional scFv CAR, EGFR Binder CAR showed significantly higher tumor-killing ability, cell proliferation ability and lower T cell exhaustion in preclinical models, and significantly prolonged the survival time of mice with orthotopic GBM xenografts without obvious toxic and side effects.

2)Treatment of Non-Small Cell Lung Cancer: For NSCLC patients with EGFR mutations, especially those with acquired resistance to EGFR-TKI, EGFR CAR-T therapy provides a new treatment option. Preclinical studies have shown that EGFR CAR-T cells can specifically recognize and kill EGFR-positive NSCLC cells, and have a good therapeutic effect in xenograft mouse models. For patients with EGFR exon 20 insertion mutation (a refractory mutation insensitive to traditional EGFR-TKI), EGFR CAR-T therapy is expected to solve the problem of poor treatment effect of existing drugs.

3)Optimization of EGFR CAR Structure: Researchers have continuously optimized the structure of EGFR CAR to improve its therapeutic effect and safety. For example, the design of masked EGFR CAR uses protease-sensitive linkers to mask the antigen-binding domain, which can be specifically activated in the tumor microenvironment, reducing off-target effects on normal EGFR-positive cells. In vitro experiments show that the expression rate of masked EGFR CAR in T cells can reach 30%-35%, which is consistent with unmasked CAR. In addition, the combination of EGFR CAR with immune checkpoint inhibitors (such as PD-1/PD-L1 inhibitors) can further enhance the anti-tumor effect of CAR-T cells and reverse T cell exhaustion.

Approved Drugs Related to EGFR CAR

At present, there are no EGFR CAR-T drugs officially approved for marketing globally, but a number of EGFR CAR-related drugs are in clinical trials (Phase I/II), covering indications such as GBM, NSCLC, and colorectal cancer. Although no EGFR CAR drugs have been approved, a variety of EGFR-targeted drugs (EGFR-TKI) have been widely used in clinical practice, providing a foundation for the combined application of EGFR CAR therapy. For example:

1) Amivantamab (Rybrevant): An EGFR/MET bispecific antibody, which was approved by the US FDA in 2026 for subcutaneous injection once a month, combined with Lazertinib for first-line treatment of advanced NSCLC with EGFR mutations. Compared with intravenous infusion, subcutaneous injection is more convenient and has lower infusion-related reactions.

2) Osimertinib (Tagrisso): A third-generation EGFR-TKI, which is the first-line standard treatment for NSCLC with EGFR sensitive mutations, but acquired resistance is a major clinical problem. The combination of EGFR CAR-T therapy and osimertinib is expected to overcome drug resistance.

3) Sunvozertinib: Approved by the US FDA in 2025 for the treatment of NSCLC patients with EGFR exon 20 insertion mutation who progressed during or after platinum-containing chemotherapy. It has a good therapeutic effect in Asian and non-Asian populations, and is also effective in patients with baseline brain metastases.

4) Apatinib: A third-generation EGFR-TKI independently developed in China. In 2026, its indication for first-line treatment combined with chemotherapy (pemetrexed + platinum) was approved in China, which significantly reduced the risk of disease progression or death and improved the objective remission rate.

With the continuous advancement of clinical trials, it is expected that the first EGFR CAR-T drug will be approved for marketing soon, bringing new hope to patients with EGFR-positive tumors.

Research Hotspots of EGFR CAR

At present, the research hotspots of EGFR CAR mainly focus on the following aspects, aiming to improve the therapeutic effect, reduce side effects and expand the scope of application.

1) Optimization of CAR Structure: Including the development of new antigen-binding domains (such as Binder instead of scFv) to improve binding affinity and stability; optimization of co-stimulatory signals to enhance T cell activation and persistence; design of masked CAR or conditional activation CAR to reduce off-target effects on normal tissues.

2) Solution to Tumor Microenvironment (TME) Suppression: The immunosuppressive tumor microenvironment (such as high expression of PD-L1, TGF-β, and accumulation of regulatory T cells) is an important factor affecting the therapeutic effect of EGFR CAR-T. Current research focuses on combining EGFR CAR with immune checkpoint inhibitors, cytokine therapy, or gene editing technology to modify T cells to resist the immunosuppressive effect of TME.

3) Combination Therapy Strategy: Combining EGFR CAR-T therapy with EGFR-TKI, chemotherapy, radiotherapy or other immunotherapies to achieve synergistic anti-tumor effect. For example, the combination of EGFR CAR-T and Amivantamab + Lazertinib can further improve the therapeutic effect of NSCLC patients with EGFR mutations and delay drug resistance.

4) Application in Refractory Tumors: Focusing on the research of EGFR CAR in refractory tumors such as EGFR exon 20 insertion mutation NSCLC, recurrent GBM, and metastatic colorectal cancer, to solve the problem of poor treatment effect of existing therapies.

5) Mechanism Research of EGFR-Mediated Drug Resistance: Exploring the mechanism of EGFR-mediated CAR-T therapy resistance, such as EGFR downregulation, tumor cell heterogeneity, and EGFR extracellular secretion, and developing corresponding solutions. For example, the extracellular secretion of EGFR can mediate the transmission of drug resistance between tumor cells, which provides a new idea for overcoming resistance.

Research Challenges of EGFR CAR

Although EGFR CAR research has made great progress, there are still many difficulties and challenges to be solved to realize its wide clinical application:

1) Off-Target Effects and Toxic Side Effects: EGFR is moderately expressed in normal epithelial tissues. EGFR CAR-T cells may attack normal EGFR-positive cells, leading to side effects such as skin rash, diarrhea, and damage to the gastrointestinal tract. How to improve the tumor specificity of EGFR CAR and reduce off-target effects is a key challenge. Although masked CAR and other designs have made progress, there is still a need for further optimization to ensure safety.

2) Tumor Heterogeneity: EGFR expression level and mutation type in tumor tissues are highly heterogeneous. Some tumor cells may have low EGFR expression or EGFR mutation, leading to the inability of EGFR CAR-T cells to recognize and kill them, resulting in treatment failure or tumor recurrence. For example, the single targeting of EGFRvⅢ has limited effect because more than 80% of GBM patients express wild-type EGFR.

3) T Cell Exhaustion: In the process of treating solid tumors, EGFR CAR-T cells are easily inactivated or exhausted due to the stimulation of the tumor microenvironment and continuous antigen stimulation, which reduces their long-term anti-tumor effect. Although Binder CAR can reduce T cell exhaustion to a certain extent, it is still necessary to further explore more effective solutions.

4) Delivery Efficiency of CAR Vectors: The delivery efficiency of EGFR CAR expression vectors (especially viral vectors) directly affects the expression level of CAR in T cells and the therapeutic effect. How to improve the delivery efficiency, reduce the immunogenicity of vectors, and avoid insertional mutagenesis is an important technical challenge.

5) Clinical Transformation Difficulties: The translation from preclinical research to clinical application faces many problems, such as the standardization of CAR-T cell preparation, the determination of optimal dosage, the management of clinical side effects, and the high cost of treatment. In addition, the limited persistence of CAR-T cells in vivo (such as the limited persistence of CAR-TEAM cells in GBM patients) also affects the long-term therapeutic effect.

References

Contact Us